array(3) { ["company_details"]=> array(13) { ["name"]=> string(26) "Bio-RAD Laboratories, Inc." ["slug"]=> string(33) "001cd-us-bio-rad-laboratories-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920" ["description"]=> string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together. #Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics" ["address_street"]=> string(20) "1000 Alfred Nobel Dr" ["address_place"]=> string(8) "Hercules" ["address_region"]=> string(10) "California" ["founding_date"]=> string(10) "1952-02-08" ["website_domain"]=> string(11) "bio-rad.com" ["website_url"]=> string(23) "https://www.bio-rad.com" ["industry_codes"]=> array(3) { [0]=> string(42) "In Vitro and In Vivo Diagnostic Substances" [1]=> string(33) "Laboratory Analytical Instruments" [2]=> string(47) "Electromedical and Electrotherapeutic Apparatus" } ["employee_count"]=> int(7900) ["article_count"]=> int(684) } ["articles"]=> array(5) { [0]=> array(7) { ["title_en"]=> string(86) "Bio-Rad Laboratories (NYSE:BIO) Price Target Lowered to $550.00 at Credit Suisse Group" ["snippet_en"]=> string(283) "Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price objective reduced by Credit Suisse Group from $580.00 to $550.00 in a research note released on Friday, MarketBeat reports. Credit Suisse Group currently has an outperform rating on the medical research company’s stock." ["url"]=> string(126) "http://www.defenseworld.net/2023/08/08/bio-rad-laboratories-nysebio-price-target-lowered-to-550-00-at-credit-suisse-group.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/50c72367-3fea-4f09-a983-dedc3af37019" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-08-08" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(21) "Competitive Behaviour" [2]=> string(24) "Stock Research & Ratings" [3]=> string(13) "Credit Rating" } } [1]=> array(7) { ["title_en"]=> string(84) "Aigen Investment Management LP Raises Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(295) "Aigen Investment Management LP raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Rating) by 281.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,719 shares of the medical" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-bio-sec-filing-2023-05-22/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/8b63f3e1-25e8-44a4-a9a5-fe0e0340e923" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-05-22" ["categories"]=> array(3) { [0]=> string(18) "General Investment" [1]=> string(13) "Credit Rating" [2]=> string(19) "Investment Requests" } } [2]=> array(7) { ["title_en"]=> string(43) "Bio-Rad Labs A Sees RS Rating Improve To 71" ["snippet_en"]=> string(101) "Bio-Rad Labs A shows rising price performance, earning an upgrade to its IBD Relative Strength Rating" ["url"]=> string(87) "https://www.investors.com/ibd-data-stories/bio-rad-labs-a-sees-rs-rating-improve-to-71/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f2967566-092c-4dc9-a495-034ea9ad6617" ["source"]=> string(13) "investors.com" ["publication_date"]=> string(10) "2023-03-28" ["categories"]=> array(1) { [0]=> string(13) "Credit Rating" } } [3]=> array(7) { ["title_en"]=> string(78) "Mackenzie Financial Corp Raises Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(222) "Mackenzie Financial Corp grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 104.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission." ["url"]=> string(109) "https://reporter.am/2022/12/24/mackenzie-financial-corp-raises-stake-in-bio-rad-laboratories-inc-nysebio.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/80fb72c7-63e5-47d1-a1ef-5b0344afb1d8" ["source"]=> string(11) "reporter.am" ["publication_date"]=> string(10) "2022-12-24" ["categories"]=> array(1) { [0]=> string(13) "Credit Rating" } } [4]=> array(7) { ["title_en"]=> string(70) "Fitch Affirms Bio-Rad Laboratories Inc.'s IDR at 'BBB'; Outlook Stable" ["snippet_en"]=> string(155) "Fitch Ratings-New York-16 September 2021: Fitch Ratings has affirmed Bio-Rad Laboratories, Inc.'s Long-Term Issuer-Default Rating (IDR) at 'BBB'. The compa" ["url"]=> string(131) "https://www.fitchratings.com/research/corporate-finance/fitch-affirms-bio-rad-laboratories-inc-idr-at-bbb-outlook-stable-16-09-2021" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bfb0a8b2-ba17-4d69-b4dd-d154edd6c594" ["source"]=> string(16) "fitchratings.com" ["publication_date"]=> string(10) "2021-09-16" ["categories"]=> array(1) { [0]=> string(13) "Credit Rating" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(66) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(51) } [2]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(32) } [3]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(30) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(26) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(24) } [6]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(23) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(20) } [8]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(20) } [9]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(19) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(19) } [11]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(18) } [12]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(15) } [13]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(14) } [14]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [15]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(13) } [16]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(10) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(10) } [18]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(9) } [19]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(9) } [20]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(8) } [21]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(7) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(7) } [23]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(7) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(7) } [25]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(6) } [26]=> array(2) { ["name"]=> string(13) "Credit Rating" ["count"]=> int(5) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(5) } [28]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(5) } [29]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(5) } } } 001cd-us-bio-rad-laboratories-inc